CD19 and B-cell chronic lymphocytic leukemia: To assess whether the combinatorial therapy may affect primary CD19 positive lymphocytes from CLL patients, we treated freshly isolated CD19 positive CLL cells with JQ1, and venetoclax alone or the combination of the two drugs.